On March 6, 2023, the teams led by Professor Han Jianfeng and Professor Yu Jia from Department of Neurology, for the first time, applied novel dense-mesh stent (Surpass Evolve flow diverter) in the treatment of two patients with large unruptured intracranial aneurysms in the internal carotid artery in northwest China.

The first patient suffered from intermittent headache for 1 year. Cranial MRA and CTA two weeks ago revealed an aneurysm in the C5 segment of the right internal carotid artery (approximately 18×13 mm). The second patient developed paroxysmal dizziness for 2 days. Cranial MRA revealed an aneurysm (roughly 17×12 mm) in the C6 segment of the right internal carotid artery. Both two patients sought for further treatment in Department of Neurology of the First Affiliated Hospital of Xi’an Jiaotong University (XJTU).

After comprehensive preoperative examination, preoperative discussion and drug preparation, Professor Han Jianfeng and Professor Yu Jia along with team members cooperated with Department of Anesthesiology and Perioperative Medicine and Interventional Operating Room to perform the implantation of Surpass Evolve flow diverter for two patients under general anesthesia. The surgery was successfully completed and the stent properly adhered to the wall. Postoperatively, two patients were transferred to ICU of Department of Neurology for intimate observation, and then transferred to routine ward the next day. At present, two patients were discharged after proper recovery.

MRA and CTA of the first patient

MRA and CTA of the second patient

In recent years, with the advent of flow diverting concept, the treatment of intracranial aneurysms has been increasingly dependent on the update of dense-mesh stents. Surpass Evolve dense-mesh stent is one of the latest generation of flow diverter worldwide. Compared with the previous-generation Surpass Streamline system, it has multiple advantages of more convenient placement, smoother release and better wall adhesion,etc. It can not only improve the comfort levels of surgeons, but also significantly enhance the efficacy for large or giant intracranial aneurysms and significantly lower the risk of recurrence, which provides a more effective therapeutic option forintracranial aneurysms. These two successful cases accomplished by Department of Neurology of our hospital create novel breakthrough in interventional treatment of giant intracranial aneurysms, representing the leading level of our hospital in the northwest region.